BTIG Maintains Buy on Intuitive Surgical, Raises Price Target to $513
BTIG analyst Ryan Zimmerman maintains Intuitive Surgical (NASDAQ:ISRG) with a Buy and raises the price target from $454 to $513.
Follow the latest Intuitive Surgical Inc. (ISRG) news and market headlines alongside the live ISRG price. Stay informed on what's moving ISRG.
BTIG analyst Ryan Zimmerman maintains Intuitive Surgical (NASDAQ:ISRG) with a Buy and raises the price target from $454 to $513.
Intuitive Surgical (NASDAQ:ISRG) has outperformed the market over the past 20 years by 11.51% on an annualized basis producing an average annual return of 20.31%. Currently, Intuitive Surgical has a market
10x Genomics announced that Fudan University Shanghai Cancer Center and Shanghai Precision Diagnostics will use its Xenium platform in a 24-month breast cancer biomarker study analyzing tumor biopsies from 500 patients. The collaboration aims to identify biomarkers predicting treatment response to neoadjuvant therapy, potentially advancing personalized cancer diagnostics. TXG stock has surged 264.7% year-to-date, outperforming broader markets.
AMN Healthcare (AMN) is well-positioned for growth driven by strong healthcare staffing demand, MSP opportunities, and technology investments, with Nurse and Allied revenues rising 27% in Q3. However, the stock faces headwinds from visa delays affecting international nurse placements, pricing pressures, and weakness in Physician and Technology segments. The company holds a Zacks Rank #3 (Hold) rating despite surging 140.5% year-to-date.
Merit Medical Systems announced positive real-world clinical data from its WRAPSODY Cell-Impermeable Endoprosthesis, demonstrating 92.7% six-month target lesion primary patency and 76.7% access circuit primary patency, both exceeding WAVE trial results. The device received FDA approval in December 2024 and is now being commercialized in the U.S., with ongoing registry studies expected to generate comprehensive clinical evidence supporting wider physician adoption in the growing dialysis access market.
CONMED (CNMD) is positioned for growth through its high-margin platforms like AirSeal, Buffalo Filter, and BioBrace, supported by expanding surgical adoption and favorable legislation. However, the company faces near-term challenges including U.S. orthopedic weakness, tariff pressures, and OEM business volatility. 2026 EPS estimates were raised to $4.58 per share despite headwinds.
Intuitive Surgical agreed to a $450 million no-fault settlement over third-party da Vinci servicing and instrument remanufacturing. While the settlement reduced Q3 GAAP EPS to $1.49, adjusted EPS rose 25% year-over-year to $3.00. Revenues grew 22% to $3 billion with procedures up 15%, demonstrating strong underlying operational momentum despite the litigation charge.
Intuitive Surgical (ISRG) is highlighted as a solid growth stock with a Zacks Rank #2 (Buy) and Growth Score of A. The company demonstrates strong fundamentals including projected EPS growth of 25.8% (vs. 12% industry average), year-over-year cash flow growth of 15.8% (vs. 0.9% industry average), and positive earnings estimate revisions with a 5.6% surge over the past month.
Alcon Inc. (ALC) reported Q3 2026 core EPS of 91 cents, beating estimates by 2.3%, but net sales of $2.72 billion missed consensus by 0.6%. While Vision Care and Equipment segments showed strength, Implantables sales declined 2% due to competitive pressures. The company narrowed its 2026 guidance, expecting 6% constant-currency net sales growth and 12-14% core EPS growth, which weighed on investor sentiment.
Inspire Medical Systems (INSP) is positioned for solid growth despite a 32.5% year-to-date stock decline. The company faces near-term headwinds from $120 million in annual coding and reimbursement disruptions, but benefits from strong Inspire V adoption, improved clinical evidence, and a new CPT code effective in 2028. Project Horizon initiatives are expected to support low-single-digit revenue growth in 2027, though GLP-1 adoption and international weakness remain concerns.
Waters Corporation received FDA 510(k) clearance for its BD OneFlow LST Test and BD OneFlow B-CLPD T1 Test, ready-to-use flow cytometry tests designed to diagnose B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. The tests deliver 96.3% sensitivity and 98.2% specificity, reduce manual steps by 95%, and are expected to launch commercially in spring 2027. The stock rose 2.9% following the announcement.
Following a significant market sell-off where the Nasdaq-100 fell 6.36% on Thursday, the index rebounded 3.40% on Monday. The article advocates for maintaining an optimistic, long-term investment approach during market downturns, emphasizing that patient investors who continue buying through dips have historically benefited. Historical examples include Intuitive Surgical rising 53-fold since 2006 and MercadoLibre rising more than fivefold since 2009 when purchased during market corrections.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to ISRG, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.